摘要
目的:系统评价选择性5-羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)治疗肠易激综合征(irritable bowel syndrome,IBS)的有效性及安全性.方法:计算机检索PubMed、Embase、Cochrane图书馆临床对照试验数据库、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI),查找SSRI治疗肠易激综合征的所有随机对照试验(randomized controlledtrials,RCTs),应用Cochrane协作网提供的Revman5.0软件进行分析评价.结果:共纳入5项试验,共300例患者.治疗使用的药物包括氟西汀、西酞普兰、帕罗西汀.RCT表明,SSRI改善IBS总体症状缓解率无统计学意义[RR=2.09,95%CI=(0.97,4.47),P<0.05];严重不良反应的发生率与安慰剂组相比无明显统计学差异[RR=1.38,95%CI=(0.68,2.82),P>0.05].结论:SSRI对缓解IBS患者的总体症状与安慰剂相比未见明显疗效差别,不良事件发生率无统计学意义.
AIM： To systematically assess the efficacy and safety of selective serotonin reuptake inhibitor（SSRI） antidepressants（SSRIs） for irritable bowel syndrome（IBS）.METHODS： PubMed,Embase,the Cochrane Central Register of Controlled Trials,Chinese Biomedical Literature Database,and China Journal Full-text Database were searched for randomized controlled trials investigating the efficacy of SSRIs in the management of IBS.The Revman 5.0 software provided by the Cochrane Collaboration was used for assessment.RESULTS： Five placebo-controlled,doubleblind,randomized trials including 300 patients were involved in this analysis.SSRIs used in,these studies included citalopram,fluoxetine and paroxetine.Compared to placebo,SSRIs were not associated with a statistically significant global symptom relief [RR = 2.09,95%CI =（0.97,4.47）,P 〈 0.05].There was no significant difference in the incidence of serious adverse events between the SSRIs and placebo groups [RR = 1.38,95%CI =（0.68,2.82）,P 〉 0.05].CONCLUSION： There are no significant differences in IBS symptom improvement and incidence of side effects between SSRI and placebo groups.
出处
《世界华人消化杂志》
CAS
北大核心
2012年第22期2106-2110,共5页
World Chinese Journal of Digestology
